Long-term quality of life after liver transplantation for non-resectable colorectal metastases confined to the liver.
Adult
Cancer Pain
/ diagnosis
Carcinoma
/ complications
Colorectal Neoplasms
/ complications
Disease-Free Survival
Fatigue
/ diagnosis
Health Status
Humans
Liver Neoplasms
/ complications
Liver Transplantation
Middle Aged
Pilot Projects
Quality of Life
Severity of Illness Index
Surveys and Questionnaires
/ statistics & numerical data
Journal
BJS open
ISSN: 2474-9842
Titre abrégé: BJS Open
Pays: England
ID NLM: 101722685
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
01
06
2018
accepted:
20
09
2018
entrez:
9
4
2019
pubmed:
9
4
2019
medline:
9
4
2019
Statut:
epublish
Résumé
Liver transplantation for patients with non-resectable colorectal liver metastases offers increased survival, with median overall survival of more than 5 years. The aim of this study was to compare quality of life before and up to 3 years after liver transplantation for colorectal liver metastases. Quality of life was assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire version 3.0. The patients received the questionnaire before and up to 3 years after liver transplantation. Some 23 patients were included in the analysis. Three months after liver transplantation they reported reduced quality of life (global health status scale), physical function and role function, and increased dyspnoea. At 6 months, global health status, physical function and role function had returned to pretransplant values. Three years after liver transplantation all symptom and function scores were comparable to baseline values. Patients with high scores for fatigue, pain and appetite loss at baseline had reduced 3-year overall survival. Patients with non-resectable colorectal liver-only metastases receiving liver transplantation had good long-term quality of life. Patients with high symptom scores before transplantation had reduced 3-year overall survival.
Sections du résumé
Background
Liver transplantation for patients with non-resectable colorectal liver metastases offers increased survival, with median overall survival of more than 5 years. The aim of this study was to compare quality of life before and up to 3 years after liver transplantation for colorectal liver metastases.
Methods
Quality of life was assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire version 3.0. The patients received the questionnaire before and up to 3 years after liver transplantation.
Results
Some 23 patients were included in the analysis. Three months after liver transplantation they reported reduced quality of life (global health status scale), physical function and role function, and increased dyspnoea. At 6 months, global health status, physical function and role function had returned to pretransplant values. Three years after liver transplantation all symptom and function scores were comparable to baseline values. Patients with high scores for fatigue, pain and appetite loss at baseline had reduced 3-year overall survival.
Conclusion
Patients with non-resectable colorectal liver-only metastases receiving liver transplantation had good long-term quality of life. Patients with high symptom scores before transplantation had reduced 3-year overall survival.
Identifiants
pubmed: 30957065
doi: 10.1002/bjs5.50116
pii: BJS550116
pmc: PMC6433324
doi:
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
180-185Références
Eur J Cancer. 1995 Dec;31A(13-14):2260-3
pubmed: 8652253
J Clin Oncol. 2012 May 20;30(15):1755-62
pubmed: 22473155
Scand J Caring Sci. 2012 Dec;26(4):713-9
pubmed: 22452269
J Surg Oncol. 2010 Jan 1;101(1):47-53
pubmed: 19798686
Clin Liver Dis. 2011 Nov;15(4):699-715
pubmed: 22032524
Eur J Cancer. 2013 Jan;49(2):439-48
pubmed: 23116683
Eur J Cancer. 2003 Mar;39(5):587-94
pubmed: 12628837
Liver Int. 2014 Oct;34(9):1298-313
pubmed: 24703371
Br J Surg. 2016 Apr;103(5):590-9
pubmed: 26780341
Ann Surg. 2015 May;261(5):956-60
pubmed: 24950280
Transplantation. 2006 Jan 15;81(1):64-70
pubmed: 16421478
Ann Surg Oncol. 2016 Sep;23(9):2905-13
pubmed: 27016293
Transplant Proc. 1991 Feb;23(1 Pt 2):1567-8
pubmed: 1989293
J Natl Cancer Inst. 2011 Jan 5;103(1):21-30
pubmed: 21123833
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Clin Oncol. 2010 Oct 1;28(28):4384-9
pubmed: 20713853
Br J Surg. 2018 May;105(6):736-742
pubmed: 29532908
Ann Surg. 2013 May;257(5):800-6
pubmed: 23360920
Ann Surg Oncol. 2015 Aug;22(8):2761-71
pubmed: 25572686
Br J Surg. 2006 Apr;93(4):465-74
pubmed: 16523446
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
J Clin Oncol. 2011 May 20;29(15):2011-9
pubmed: 21502544
Transpl Int. 2008 Dec;21(12):1107-17
pubmed: 18713148
J Hepatol. 2012 Sep;57(3):675-88
pubmed: 22609307
Ann Surg. 2013 May;257(5):807-15
pubmed: 23532105
Lancet Oncol. 2009 Jan;10(1):35-43
pubmed: 19058754
Br J Surg. 2011 Apr;98(4):565-71; discussion 571-2
pubmed: 21656721
J Clin Oncol. 2010 Nov 1;28(31):4697-705
pubmed: 20921465
Br J Surg. 2006 Aug;93(8):1007-14
pubmed: 16739102